Nac effervescent tablets    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
90Retinitis pigmentosa1

90. Retinitis pigmentosa    [ 103 clinical trials,   158 drugs,   (DrugBank: 42 drugs),   52 drug target genes,   107 drug target pathways]
Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 103 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03999021
(ClinicalTrials.gov)
June 24, 201924/6/2019FIGHT-RP 1 Extension StudyA Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis PigmentosaRetinitis PigmentosaDrug: NAC effervescent tabletsJohns Hopkins UniversityNULLActive, not recruiting18 YearsN/AAll30Phase 1United States